Cullinan Oncology Analyst Ratings
Cullinan Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/06/2023 | 154.92% | JonesTrading | → $22 | Initiates Coverage On | → Buy |
| 08/11/2023 | 293.97% | HC Wainwright & Co. | $49 → $34 | Reiterates | Buy → Buy |
| 08/09/2023 | 467.79% | HC Wainwright & Co. | → $49 | Reiterates | → Buy |
| 07/07/2023 | 467.79% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 06/15/2023 | — | TD Cowen | Initiates Coverage On | → Outperform | |
| 06/05/2023 | 467.79% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 05/26/2023 | 467.79% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 05/12/2023 | 467.79% | HC Wainwright & Co. | $50 → $49 | Maintains | Buy |
| 03/27/2023 | 479.37% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 03/10/2023 | 479.37% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/15/2023 | 479.37% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/03/2023 | 120.16% | Morgan Stanley | $27 → $19 | Maintains | Overweight |
| 11/21/2022 | 131.75% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/13/2022 | 189.69% | SVB Leerink | $36 → $25 | Maintains | Outperform |
| 03/18/2022 | 514.14% | HC Wainwright & Co. | $55 → $53 | Maintains | Buy |
| 06/07/2021 | 398.26% | Morgan Stanley | $40 → $43 | Maintains | Overweight |
| 06/04/2021 | 537.31% | HC Wainwright & Co. | $48 → $55 | Maintains | Buy |
| 06/04/2021 | 525.72% | SVB Leerink | $48 → $54 | Maintains | Outperform |
| 04/27/2021 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 04/19/2021 | 363.5% | Morgan Stanley | $38 → $40 | Maintains | Equal-Weight |
| 03/30/2021 | 456.2% | HC Wainwright & Co. | $47 → $48 | Maintains | Buy |
| 02/02/2021 | 537.31% | Evercore ISI Group | → $55 | Initiates Coverage On | → Outperform |
| 02/02/2021 | 502.55% | SVB Leerink | → $52 | Initiates Coverage On | → Outperform |
| 02/02/2021 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 02/01/2021 | 444.61% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2023 年 6 月 10 日 | 154.92% | JonesTrading | → 22 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/11/2023 | 293.97% | HC Wainwright & Co. | 49 美元 → 34 美元 | 重申 | 購買 → 購買 |
| 08/09/2023 | 467.79% | HC Wainwright & Co. | → 49 美元 | 重申 | → 購買 |
| 07/07/2023 | 467.79% | HC Wainwright & Co. | → 49 美元 | 重申 | 購買 → 購買 |
| 06/15/2023 | — | TD Cowen | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 06/05/2023 | 467.79% | HC Wainwright & Co. | → 49 美元 | 重申 | 購買 → 購買 |
| 05/26/2023 | 467.79% | HC Wainwright & Co. | → 49 美元 | 重申 | 購買 → 購買 |
| 05/12/2023 | 467.79% | HC Wainwright & Co. | 50 美元 → 49 美元 | 維護 | 購買 |
| 03/27/2023 | 479.37% | HC Wainwright & Co. | → 50 美元 | 重申 | → 購買 |
| 03/10/2023 | 479.37% | HC Wainwright & Co. | → 50 美元 | 重申 | → 購買 |
| 02/15/2023 | 479.37% | HC Wainwright & Co. | → 50 美元 | 重申 | → 購買 |
| 02/03/2023 | 120.16% | 摩根士丹利 | 27 美元 → 19 美元 | 維護 | 超重 |
| 11/21/2022 | 131.75% | BTIG | → 20 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 05/13/2022 | 189.69% | SVB Leerink | 36 美元 → 25 美元 | 維護 | 跑贏大盤 |
| 03/18/2022 | 514.14% | HC Wainwright & Co. | 55 美元 → 53 美元 | 維護 | 購買 |
| 06/07/2021 | 398.26% | 摩根士丹利 | 40 美元 → 43 美元 | 維護 | 超重 |
| 2021 年 4 月 6 日 | 537.31% | HC Wainwright & Co. | 48 美元 → 55 美元 | 維護 | 購買 |
| 2021 年 4 月 6 日 | 525.72% | SVB Leerink | 48 美元 → 54 美元 | 維護 | 跑贏大盤 |
| 04/27/2021 | — | 摩根士丹利 | 升級 | 重量相等 → 超重 | |
| 2021 年 4 月 19 日 | 363.5% | 摩根士丹利 | 38 美元 → 40 美元 | 維護 | 等重 |
| 03/30/2021 | 456.2% | HC Wainwright & Co. | 47 美元 → 48 美元 | 維護 | 購買 |
| 02/02/2021 | 537.31% | Evercore ISI 集團 | → 55 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 02/02/2021 | 502.55% | SVB Leerink | → 52 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 02/02/2021 | — | 摩根士丹利 | 啓動覆蓋範圍開啓 | → 重量相等 | |
| 2021 年 1 月 2 日 | 444.61% | HC Wainwright & Co. | → 47 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Cullinan Oncology (CGEM)?
庫裏南腫瘤學（CGEM）的目標價格是多少？
The latest price target for Cullinan Oncology (NASDAQ: CGEM) was reported by JonesTrading on October 6, 2023. The analyst firm set a price target for $22.00 expecting CGEM to rise to within 12 months (a possible 154.92% upside). 13 analyst firms have reported ratings in the last year.
JonesTrading於2023年10月6日公佈了庫裏南腫瘤學（納斯達克股票代碼：CGEM）的最新目標股價。該分析公司將目標股價定爲22.00美元，預計CGEM將在12個月內上漲至22.00美元（可能上漲154.92％）。去年有13家分析公司公佈了評級。
What is the most recent analyst rating for Cullinan Oncology (CGEM)?
庫裏南腫瘤學（CGEM）的最新分析師評級是多少？
The latest analyst rating for Cullinan Oncology (NASDAQ: CGEM) was provided by JonesTrading, and Cullinan Oncology initiated their buy rating.
庫裏南腫瘤學（納斯達克股票代碼：CGEM）的最新分析師評級由瓊斯貿易提供，庫裏南腫瘤學啓動了買入評級。
When is the next analyst rating going to be posted or updated for Cullinan Oncology (CGEM)?
庫裏南腫瘤學（CGEM）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Oncology was filed on October 6, 2023 so you should expect the next rating to be made available sometime around October 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與庫裏南腫瘤學的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。庫裏南腫瘤學的最新評級是在2023年10月6日提交的，因此您應該預計下一個評級將在2024年10月6日左右公佈。
Is the Analyst Rating Cullinan Oncology (CGEM) correct?
分析師對庫裏南腫瘤學（CGEM）的評級是否正確？
While ratings are subjective and will change, the latest Cullinan Oncology (CGEM) rating was a initiated with a price target of $0.00 to $22.00. The current price Cullinan Oncology (CGEM) is trading at is $8.63, which is within the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的庫裏南腫瘤學（CGEM）評級是啓動的，目標股價爲0.00美元至22.00美元。庫裏南腫瘤學（CGEM）目前的交易價格爲8.63美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。